Vanderbilt Ingram Cancer Center Archive — Page 3 of 48

For more VICC news, visit their website »

photo of William Dupont
June 5, 2023

Study discovers that tumor mutation burden predicts survival outcome

The expected course of a patient’s cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers from Vanderbilt-Ingram Cancer Center have discovered that differences in tumor mutation burden are a major reason for this divergence.

By Tom Wilemon
May 31, 2023

Liquid biopsy test may detect early-stage and low DNA-shedding cancers

Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.

By Tom Wilemon
May 11, 2023

Lovly elected to American Association for Cancer Research board

Christine Lovly, MD, PhD, has been elected to the American Association for Cancer Research board of directors.

By Tom Wilemon
April 27, 2023

Trial combines novel therapies for head and neck cancer

Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.

By Tom Wilemon
April 26, 2023

VICC Scientific Retreat focuses on emerging technologies

The Vanderbilt-Ingram Cancer Center 24th Annual Scientific Retreat will be held from 8:30 am to 3 pm, May 23, in the Vanderbilt Student Life Center.

By Tom Wilemon
Jordan Berlin, MD, was recognized for his leadership serving on an NCI team that researched and recommended changes to clinical trial protocols that expanded the role of advanced practice providers.
April 6, 2023

National Cancer Institute honors Berlin’s contributions, leadership

Vanderbilt’s Jordan Berlin, MD, is a 2022 recipient of the National Cancer Institute Director’s Award.

By Tom Wilemon